Sangamo Therapeutics (SGMO) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
Financial Fact:
Research and development: 17.01M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Research and development: 17.01M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.88 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Box (BOX) Reports In-Line Q2 EPS; offers guidance
- Deutsche Bank sees stabilization in European MedTech and Life Sciences
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
